Welcome to our dedicated page for Liquidia news (Ticker: LQDA), a resource for investors and traders seeking the latest updates and insights on Liquidia stock.
Liquidia Corporation develops and commercializes therapies for respiratory and vascular diseases, with a focus on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its updates center on YUTREPIA® (treprostinil) inhalation powder, the company’s PRINT® Technology-enabled approved therapy, along with L606, an investigational extended-release treprostinil formulation administered with a nebulizer, and generic Treprostinil Injection for PAH.
Recurring news includes financial results, YUTREPIA commercial uptake, clinical data presentations, pipeline studies, corporate presentations and investor conference participation. Company updates also discuss treprostinil delivery, PAH and PH-ILD treatment settings, cash generation and profitability as product sales become a larger part of Liquidia’s operating profile.
Liquidia Corporation (NASDAQ: LQDA) reported a favorable District Court ruling regarding U.S. Patent No. 9,593,066 (‘066 Patent) but an unfavorable outcome for U.S. Patent No. 10,716,793 (‘793 Patent). The court found five of six asserted claims of the ‘066 patent invalid and ruled that the valid claim was not infringed. All claims of the '793 patent were previously invalidated by the PTAB, impacting the FDA approval pathway for YUTREPIA™ (treprostinil) inhalation powder. The company plans to appeal the decision and has scheduled a conference call for September 1, 2022.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of inducement stock options totaling 7,000 shares to newly hired non-executive employees under the 2022 Inducement Plan. Each option is priced at $7.44 per share, the closing price on August 19, 2022. The options have a vesting schedule of four years, with 25% vesting on the first anniversary and the remainder vesting monthly. This grant aligns with Nasdaq Listing Rule 5635(c)(4) to attract new talent. Liquidia focuses on developing products for pulmonary hypertension and other applications of its PRINT® Technology.
Liquidia Corporation (NASDAQ: LQDA) reported its second-quarter financial results for 2022, showing revenues of $3.9 million, up from $3.4 million the previous year. The company has strengthened its financial position with $103.8 million in cash, thanks to a recent equity offering of $54.5 million. Liquidia is focusing on launching YUTREPIA™ inhalation powder, pending regulatory approval, after a favorable ruling in Hatch-Waxman litigation. The company expects to seek a second indication for YUTREPIA in 2024 without additional studies.
Liquidia Corporation (NASDAQ: LQDA) will announce its second quarter 2022 financial results on August 11, 2022, with a conference call scheduled for 8:30 a.m. ET. The call will cover financial results and a corporate update. Interested parties can join by phone or access a webcast, which will be archived for 30 days. Liquidia focuses on developing treatments for pulmonary hypertension, including its inhalation powder YUTREPIA™. For more information, visit Liquidia's website.
Liquidia Corporation (NASDAQ: LQDA) released clinical data from the INSPIRE study on YUTREPIA™ (treprostinil) inhalation powder for pulmonary arterial hypertension (PAH). The study demonstrated effective titration, achieving therapeutic levels within two months, and maintaining safety with primarily mild to moderate side effects. Out of 121 patients, 93% completed the two-month phase, with significant improvement in NYHA functional class. Although the study wasn't designed for definitive efficacy conclusions, preliminary results indicate positive clinical impact. Long-term safety data will continue to emerge from ongoing studies.
Liquidia Corporation (NASDAQ: LQDA) will participate in two upcoming investor conferences: the BTIG Biotechnology Conference 2022 on August 8 in New York, featuring CFO Michael Kaseta's live Fireside Chat at 2:00 p.m., and the Wedbush PacGrow 2022 Healthcare Conference on August 9, a virtual event. The biopharmaceutical firm specializes in pulmonary hypertension treatments, including its product YUTREPIA™ (treprostinil) inhalation powder. More details can be found at www.liquidia.com.
Liquidia Corporation (NASDAQ: LQDA) announced the grant of a stock option for 2,000 shares to a new non-executive employee under its 2022 Inducement Plan. This option is part of the employee's compensation, aligning with Nasdaq Listing Rule 5635(c)(4). The stock option, exercisable at $5.20 per share, has a ten-year term and vests over four years, with 25% vesting after the first year and monthly vesting thereafter. Liquidia focuses on developing products for pulmonary hypertension utilizing its PRINT® Technology.
Liquidia Corporation (NASDAQ: LQDA) announced the approval of an employment inducement equity award for Dr. Rajeev Saggar, its new Chief Medical Officer. The award consists of a stock option for 200,000 shares under the Liquidia Corporation 2022 Inducement Plan, granted as a material inducement for his employment. The stock option is exercisable at $3.73 per share, with a ten-year term and a four-year vesting schedule. This strategic move aligns with Liquidia's focus on developing treatments for pulmonary hypertension and related conditions.
Liquidia Corporation (NASDAQ: LQDA) received a favorable ruling from the U.S. Patent Trial and Appeal Board regarding the unpatentability of all claims in U.S. Patent No. 10,716,793, owned by United Therapeutics Corporation. This decision supports the potential final regulatory approval of YUTREPIA, an investigational inhaled drug for pulmonary arterial hypertension (PAH). However, ongoing litigation regarding additional patents may delay YUTREPIA's approval until 2027 or later. The PTAB ruling does not guarantee resolution of the litigation.
Liquidia Corporation (LQDA) announced its inclusion in the US small-cap Russell 2000® Index effective June 27, 2022, signaling growth and increased visibility among institutional investors. This membership, valid for one year, follows Liquidia’s performance within the broader Russell 3000® Index. CEO Roger Jeffs stated this reflects the positive momentum generated over recent years, especially as the company prepares for the potential launch of YUTREPIA®, its inhalation powder product pending FDA approval.